natgillin/translations-raw huggingface dataset:
Elvitegravir was negative in an in vitro bacterial mutagenicity test (Ames test) and negative in an in vivo rat micronucleus assay at doses up to 2,000 mg/kg. 
Elvitegravir je bio negativan u in vitro pretrazi bakterijske mutagenosti (Amesov test) i negativan u in vivo analizi mikronukleusa štakora u dozama do 2000 mg/kg.
suicidal ideation and suicide attempt (in patients with a pre-existing history of depression or psychiatric illness), depression2 
suicidalne ideacije i pokušaj suicida (u bolesnika s depresijom ili psihijatrijskom bolešću u anamnezi), depresija2
 If you notice the side effects described above, tell your doctor immediately. 
 Ako primijetite gore opisane nuspojave, odmah o tome obavijestite liječnika.
Following oral administration of [14C]-elvitegravir/ritonavir, 94.8% of the dose was recovered in faeces, consistent with the hepatobiliary excretion of elvitegravir; 6.7% of the administered dose was recovered in urine. 
Nakon peroralne primjene [14C]elvitegravira/ritonavira, 94,8% doze izolirano je u stolici, što je u skladu s hepatobilijarnom ekskrecijom elvitegravira; 6,7% primijenjene doze izolirano je u urinu.
Patients should be informed that dizziness has been reported during treatment with Genvoya. 
Bolesnike treba obavijestiti da je zabilježena omaglica tijekom liječenja lijekom Genvoya.
Taking into account the PRAC Assessment Report on the PSUR(s) for cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide, the scientific conclusions of CHMP are as follows: 
Uzimajući u obzir PRAC-ovo izvješće o ocjeni periodičkog(ih) izvješća o neškodljivosti lijeka (PSUR) za kobicistat/elvitegravir/emtricitabin/tenofoviralafenamid, znanstveni zaključci CHMP-a su sljedeći:
It is important not to miss a dose of Genvoya. 
Važno je da ne propustite uzeti dozu lijeka Genvoya.
Tenofovir alafenamide is active against hepatitis B virus (HBV). 
Tenofoviralafenamid djeluje protiv virusa hepatitisa B (HBV).
The interactions described are based on studies conducted with Genvoya, or the components of Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide), as individual agents and/or in combination, or are potential drug-drug interactions that may occur with Genvoya. 
Opisane interakcije temelje se na ispitivanjima koja su provedena s lijekom Genvoya ili komponentama lijeka Genvoya (elvitegravirom, kobicistatom, emtricitabinom i tenofoviralafenamidom) kao pojedinačnim tvarima i/ili u kombinaciji, ili su potencijalne interakcije lijekova koje se mogu pojaviti s lijekom Genvoya.
When administering with Genvoya, the maximum daily dose of itraconazole should not exceed 200 mg per day. 
Kod primjene s lijekom Genvoya maksimalna dnevna doza itrakonazola ne smije biti veća od 200 mg na dan.
Do not stop taking Genvoya without talking to your doctor. 
Nemojte prestati uzimati lijek Genvoya bez prethodnog razgovora sa svojim liječnikom.
• antibiotics, used to treat bacterial infections including tuberculosis, containing: rifabutin, clarithromycin and telithromycin 
• antibiotike, primjenjuju se za liječenje bakterijskih infekcija, uključujući i tuberkulozu, a koji sadržavaju: rifabutin, klaritromicin i telitromicin
Five subjects had virologic failure through the end of the study; no phenotypic or genotypic resistance to Genvoya was detected. 
Pet bolesnika imalo je virološki neuspjeh do kraja ispitivanja; nije bila otkrivena fenotipska ili genotipska rezistencija na lijek
digoxin, disopyramide, flecainide, lidocaine, mexiletine, propafenone, metoprolol, timolol, amlodipine, diltiazem, felodipine, nicardipine, nifedipine and verapamil 
• lijekove za srce, kao što su: digoksin, dizopiramid, flekainid, lidokain, meksiletin, propafenon, metoprolol, timolol, amlodipin, diltiazem, felodipin, nicardipin, nifedipin i verapamil
These findings should be considered for any child exposed in utero to nucleos(t)ide analogues, who present with severe clinical findings of unknown aetiology, particularly neurologic findings. 
Te nalaze treba uzeti u obzir u svakog djeteta koje je in utero bilo izloženo analozima nukleozida i nukleotida, a koje je imalo tešku kliničku sliku nepoznate etiologije, osobito neurološke nalaze.
The mean age was 58 years (range 24-82), with 63 patients (26%) who were ≥ 65 years of age. 
Srednja vrijednost dobi bila je 58 godina (raspon 24-82), sa 63 bolesnika (26%) u dobi ≥ 65 godina.
Do not stop taking Genvoya 
Nemojte prestati uzimati lijek Genvoya
No dose adjustment of Genvoya is required in adults or adolescents (aged at least 12 years and of at least 35 kg body weight) with estimated creatinine clearance (CrCl) ≥ 30 mL/min. 
Nije potrebna prilagodba doze lijeka Genvoya u odraslih ili adolescenata (u dobi od najmanje 12 godina i s tjelesnom težinom od najmanje 35 kg) s procijenjenim klirensom kreatinina (CrCl) ≥ 30 ml/min.
The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of elvitegravir or cobicistat has not been studied. 
Utjecaj teškog oštećenja funkcije jetre (Child Pugh, stadij C) na farmakokinetiku elvitegravira ili kobicistata nije ispitan.
In a human clinical study of 35 healthy subjects, echocardiograms performed at baseline and after receiving 150 mg cobicistat once daily for at least 15 days indicated no clinically significant change in left ventricular function. 
U kliničkim ispitivanjima kod ljudi, na 35 zdravih ispitanika ehokardiogrami obavljeni na početku i nakon primanja 150 mg kobicistata jedanput dnevno u trajanju od najmanje 15 dana nisu ukazali na klinički važnu promjenu u funkciji lijeve klijetke.
If a patient misses a dose of Genvoya by more than 18 hours, the patient should not take the missed dose and simply resume the usual dosing schedule. 
Ako bolesnik propusti uzeti dozu lijeka Genvoya u roku duljem od 18 sati, bolesnik ne treba uzeti propuštenu dozu nego jednostavno nastaviti uzimati doze prema uobičajenom rasporedu.
Similar patterns of psychiatric disorders were observed in comparative studies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF), which lists these events in its product information (studies GS-US-292-0104 or GS-US-292-0111). 
Slični uzorci psihijatrijskih poremećaja primijećeni su u usporednim ispitivanjima elvitegravira/kobicistata/emtricitabina/tenofoviralafenamida (E/C/F/TAF) naspram elvitegravira/kobicistata/emtricitabina/tenofovirdizoproksilfumarata (E/C/F/TDF), što je dovelo do uvrštavanja ovih događaja u informacije o lijeku (ispitivanje GS-US-292-0104 ili GS-US-292-0111).
Elvitegravir, cobicistat, and emtricitabine have all demonstrated low carcinogenic potential in mice and rats. 
Elvitegravir, kobicistat i emtricitabin pokazali su nisku razinu kancerogenosti u miševa i štakora.
The results reported from a prospective study (IMPAACT P1026s) showed that treatment with cobicistat and elvitegravir-containing regimens during pregnancy results in lower elvitegravir and cobicistat exposures (Table 7). 
Prijavljeni rezultati prospektivnog ispitivanja (IMPAACT P1026s) pokazali su da liječenje režimima koji sadrže kobicistat i elvitegravir tijekom trudnoće rezultira nižom izloženošću elvitegraviru i kobicistatu (Tablica 7).
There are no or limited data (less than 300 pregnancy outcomes) from the use of Genvoya in pregnant women. 
Nema podataka ili su podaci o primjeni lijeka Genvoya u trudnica ograničeni (manje od 300 trudnoća).
Elvitegravir, emtricitabine, and tenofovir alafenamide demonstrated synergistic antiviral activity in cell culture. 
Elvitegravir, emtricitabin i tenofoviralafenamid pokazuju sinergističko antivirusno djelovanje u staničnoj kulturi.
Tenofovir alafenamide is not an inhibitor or inducer of CYP3A in vivo. 
Tenofoviralafenamid nije inhibitor ni induktor CYP3A in vivo.
 If any of these applies to you, talk to your doctor before taking Genvoya. 
Ako se bilo što od ovog odnosi na Vas, razgovarajte sa svojim liječnikom prije nego uzmete lijek Genvoya.
HIV-1 with the raltegravir-selected substitutions T66A/K, Q148H/K, and N155H showed cross-resistance to elvitegravir. 
HIV-1 sa supstitucijama izdvojenim raltegravirom T66A/K, Q148H/K i N155H pokazao je križnu rezistenciju na elvitegravir.
Table 3: Pooled virologic outcomes of studies GS-US-292-0104 and GS-US-292-0111 at Weeks 48 and 144a,b 
Tablica 3: Objedinjeni virološki ishodi u ispitivanjima GS-US-292-0104 i GS-US-292-0111 u 48. i 144. tjednua,b
Following oral administration of [14C]-cobicistat, 99% of circulating radioactivity in plasma was unchanged cobicistat. 
Nakon peroralne primjene [14C]-kobicistata, 99% cirkulirajuće radioaktivnosti u plazmi predstavljao je nepromijenjeni kobicistat.
Of the patients who were HBsAg positive at baseline, 3/70 (4.3%) achieved seroconversion to anti-HBs at Week 48. 
Od bolesnika koji su pri ishodištu bili HBsAg pozitivni, 3/70 (4,3%) postiglo je serokonverziju u anti-HBs u 48. tjednu.
Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6. 
Tenofoviralafenamid nije inhibitor CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 ili CYP2D6.
Therefore, Genvoya should not be used during breast-feeding. 
Stoga se Genvoya ne smije primjenjivati tijekom dojenja.
In vitro, tenofovir alafenamide is not metabolised by CYP1A2, CYP2C8, CYP2C9, CYP2C19, or CYP2D6. 
In vitro se tenofoviralafenamid ne metabolizira pomoću CYP1A2, CYP2C8, CYP2C9, CYP2C19 ili CYP2D6.
Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as elvitegravir, where bioavailability is limited and half-life is shortened by CYP3A-dependent metabolism. 
Inhibicija CYP3A posredovanog metabolizma s kobicistatom pojačava sistemsku izloženost supstratima CYP3A, kao što je elvitegravir, čija je bioraspoloživost ograničena, a poluvrijeme skraćeno metabolizmom koji ovisi o CYP3A.
If you forget to take Genvoya 
Ako ste zaboravili uzeti lijek Genvoya
In human clinical studies, a 10 mg oral dose of tenofovir alafenamide in Genvoya resulted in tenofovir diphosphate concentrations > 4-fold higher in PBMCs and > 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) in E/C/F/TDF. 
U kliničkim ispitivanjima u ljudi, peroralna doza od 10 mg tenofoviralafenamida u lijeku Genvoya rezultira koncentracijama tenofovirdifosfata > 4 puta većima u PBMC-ovima i > 90% manjim koncentracijama tenofovira u plazmi u usporedbi s peroralnom dozom tenofovirdizoproksila (u obliku fumarata) od 245 mg u E/C/F/TDF.
• sedatives and hypnotics, used to treat anxiety: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem and lorazepam 
• sedative i hipnotike, primjenjuju se za liječenje tjeskobe: buspiron, klorazepat, diazepam, estazolam, flurazepam, zolpidem i lorazepam
Table 4: Virologic outcomes of Study GS-US-292-0109 at Weeks 48a and 96b 
Tablica 4. Virološki ishodi ispitivanja GS-US-292-0109 u 48.a i 96.b tjednu
Of the 10 patients who were not HBV suppressed at baseline (HBV DNA ≥ 29 IU/mL), 7 became suppressed, 2 remained detectable, and 1 had missing data. 
Od 10 bolesnika koji nisu imali supresiju HBV-a pri ishodištu (HBV DNA ≥ 29 IU/ml), u 7 je došlo do supresije, 2 su zadržala detektibilnost, a za 1 bolesnika podaci nisu poznati.
2 These studies were performed with ritonavir boosted elvitegravir. 
Ta su ispitivanja provedena s ritonavirom pojačanim elvitegravirom.
Overall, 22% had baseline plasma HIV-1 RNA > 100,000 copies/mL. 
Sveukupno, 22% bolesnika imalo je početnu razinu HIV-1 RNK u plazmi > 100 000 kopija/ml.
Based on this, section 4.8 of the SmPC of medicinal products containing elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide FDC has been updated to add suicidal ideation and suicide attempt (in patients with a pre-existing history of depression or psychiatric illness) as new adverse drug reactions. 
Na temelju toga je dio 4.8 sažetka opisa svojstava lijekova koji sadrže elvitegravir/kobicistat/emtricitabin/tenofoviralafenamid u fiksnoj kombinaciji ažuriran kako bi se dodale suicidalne ideacije i pokušaj suicida (u bolesnika s otprije postojećom depresijom ili psihijatrijskom bolešću u anamnezi) kao nove nuspojave na lijek.
Co-administration of Genvoya and sildenafil for the treatment of pulmonary arterial hypertension is contraindicated. 
Istodobna primjena lijeka Genvoya i sildenafila za liječenje plućne arterijske hipertenzije je kontraindicirana.
30 film-coated tablets 30 tablets 
OBLIK I SADRŽAJ 30 filmom obloženih tableta 30 tableta
Following administration of [14C]-emtricitabine, complete recovery of the emtricitabine dose was achieved in urine (~86%) and faeces (~14%). 
Nakon primjene [14C]emtricitabina, potpuna izolacija doze emtricitabina ostvarena je u urinu (~86%) i stolici (~14%).
Discontinuation of Genvoya therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis. 
Prekid terapije lijekom Genvoya u bolesnika istodobno zaraženih HIV-om i HBV-om može biti povezan s teškim akutnim egzacerbacijama hepatitisa.
The safety of elvitegravir, cobicistat, emtricitabine or tenofovir alafenamide has not been established in these patients. 
Sigurnost elvitegravira, kobicistata, emtricitabina ili tenofoviralafenamida u tih bolesnika nije ustanovljena.
b In both studies, patients were stratified by baseline HIV-1 RNA (≤ 100,000 copies/mL, > 100,000 copies/mL to ≤ 400,000 copies/mL, or > 400,000 copies/mL), by CD4+ cell count (< 50 cells/µL, 50-199 cells/µL, or ≥ 200 cells/µL), and by region (US or ex-US). 
b U oba ispitivanja bolesnici su stratificirani prema početnoj HIV-1 RNK (≤ 100 000 kopija/ml, > 100 000 kopija/ml do ≤ 400 000 kopija/ml, ili > 400 000 kopija/ml), prema broju CD4+ stanica (< 50 stanica/µl, 50-199 stanica/µl ili ≥ 200 stanica/µl) te po regiji (SAD ili izvan SAD-a).
At Week 48, the virologic response rate to Genvoya in treatment-naïve HIV-1 infected adolescents was similar to response rates in studies of treatment-naïve HIV-1 infected adults. 
U 48. tjednu stopa virološkog odgovora na lijek Genvoya u adolescenata zaraženih virusom HIV-1 koji prethodno nisu bili liječeni bila je slična stopama odgovora u ispitivanjima odraslih bolesnika zaraženih virusom HIV-1 koji prethodno nisu bili liječeni.
Based on these limited data, the safety profile of Genvoya in patients with HIV/HBV co-infection was similar to that in patients with HIV-1 monoinfection. 
Na temelju ovih ograničenih podataka, sigurnosni profil lijeka Genvoya u bolesnika koji su istodobno bili zaraženi HIV-om i HBV-om bio je sličan onome u bolesnika zaraženih samo virusom HIV-1.
On the basis of the scientific conclusions for cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide is unchanged subject to the proposed changes to the product information 
Na temelju znanstvenih zaključaka za kobicistat/elvitegravir/emtricitabin/tenofoviralafenamid, CHMP smatra da je omjer koristi i rizika lijeka(ova) koji sadrži(e) kobicistat/elvitegravir/emtricitabin/tenofoviralafenamid nepromijenjen, uz predložene izmjene informacija o lijeku.
Genvoya has not been studied in patients with severe hepatic impairment (Child-Pugh Class C); therefore, Genvoya is not recommended for use in patients with severe hepatic impairment (see sections 4.4 and 5.2). 
Genvoya nije ispitana u bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh stadij C) te se stoga primjena lijeka Genvoya ne preporučuje u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dijelove 4.4 i 5.2).
Mean % change of cobicistat pharmacokinetic parametersa 
Srednja vrijednost % promjene farmakokinetičkih parametara kobicistataa
Increased monitoring for rifabutin-associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to desacetyl-rifabutin. 
Potreban je stroži nadzor nuspojava povezanih s rifabutinom, uključujući i neutropeniju i uveitis zbog očekivanog povećanja izloženosti dezacetilrifabutinu.
Tenofovir alafenamide is mainly eliminated following metabolism to tenofovir. 
Tenofoviralafenamid se uglavnom eliminira nakon metabolizma u tenofovir.
Elvitegravir is primarily metabolised by CYP3A, and medicinal products that induce or inhibit CYP3A may affect the exposure of elvitegravir. 
Elvitegravir se prvenstveno metabolizira putem CYP3A te lijek koji inducira ili inhibira CYP3A može utjecati na izloženost elvitegraviru.
Patients were randomised in a 2:1 ratio to either switch to Genvoya at baseline (n = 959), or stay on their baseline antiretroviral regimen (n = 477). 
Bolesnici su na početku bili randomizirani u omjeru 2:1 kako bi se prebacili na lijek Genvoya (n = 959) ili ostali na svom početnom antiretrovirusnom režimu (n = 477).
In a separate Phase 1 study of emtricitabine alone, mean systemic emtricitabine exposure was higher in patients with severe renal impairment (estimated CrCl < 30 mL/min) (33.7 µg•h/mL) than in subjects with normal renal function (11.8 µg•h/mL). 
U zasebnom ispitivanju faze I samo emtricitabina, srednja vrijednost sistemske izloženosti emtricitabinu bila je viša u bolesnika s teškim oštećenjem funkcije bubrega (procijenjeni CrCl < 30 ml/min) (33,7 µg•h/ml) nego u ispitanika s normalnom funkcijom bubrega (11,8 µg•h/ml).
For the treatment of erectile dysfunction, it is recommended that a single dose of sildenafil no more than 25 mg in 48 hours, vardenafil no more than 2.5 mg in 72 hours, or tadalafil no more than 10 mg in 72 hours be co-administered with Genvoya. 
Za liječenje erektilne disfunkcije preporučuje se primjena jedne doza sildenafila od najviše 25 mg u 48 sati, vardenafila od najviše 2,5 mg u 72 sata ili tadalafila od najviše 10 mg u 72 sata istodobno s lijekom Genvoya.
Elvitegravir undergoes primarily oxidative metabolism via CYP3A, and is secondarily glucuronidated via UGT1A1/3 enzymes. 
Elvitegravir primarno prolazi kroz oksidativni metabolizam putem CYP3A i sekundarno prolazi glukuronidaciju putem enzima UGT1A1/3.
Genvoya contains lactose monohydrate. 
Genvoya sadrži laktozu hidrat.
Relative to fasting conditions, the administration of Genvoya with a light meal (~400 kcal, 20% fat) or high-fat meal (~800 kcal, 50% fat) did not affect overall exposures of tenofovir alafenamide to a clinically meaningful extent (approximately 15% and 18% higher AUC with a light or high-fat meal, respectively, versus fasted). 
U odnosu na stanje natašte, primjena lijeka Genvoya s laganim obrokom (∼400 kcal, 20%masnoće) ili visokomasnim obrokom (∼800 kcal, 50% masnoće) nije utjecala na ukupne izloženosti tenofoviralafenamidu u klinički značajnoj mjeri (otprilike 15% i 18% veći AUC uz lagani ili visokomasni obrok u odnosu na stanje natašte).
Therefore, Genvoya should not be co-administered with medicinal products that include, but are not limited to, the following (see sections 4.4 and 4.5): 
Stoga se Genvoya ne smije primjenjivati istodobno s lijekovima koji uključuju, ali nisu ograničeni na sljedeće lijekove (vidjeti dijelove 4.4 i 4.5):
Each tablet contains 61 mg lactose (as monohydrate). 
Pomoćne tvari s poznatim učinkom Jedna tableta sadrži 61 mg laktoze (u obliku hidrata).
Bone toxicity was observed as reduced bone mineral density in rats and dogs at tenofovir exposures at least 4 times greater than those expected after administration of Genvoya. 
Toksičnost za kost uočena je kao smanjena mineralna gustoća kostiju u štakora i pasa pri izloženostima tenofoviru najmanje četiri puta većima od onih očekivanih nakon primjene lijeka Genvoya.
• If you notice within 18 hours of the time you usually take Genvoya, you must take the tablet as soon as possible. 
• Ako to primijetite unutar manje od 18 sati od vremena kad obično uzimate lijek Genvoya, tabletu morate uzeti što prije.
Patients with liver disease including chronic hepatitis B or C, who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications. 
Bolesnici s bolešću jetre, uključujući kronični hepatitis B ili C, koji se liječe antiretrovirusnim lijekovima, izloženi su većemu riziku od teških i potencijalno fatalnih jetrenih komplikacija.
EFV = efavirenz; FTC = emtricitabine; E/C/F/TDF = elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate a Week 48 window was between Day 294 and 377 (inclusive). 
EFV = efavirenz; FTC = emtricitabin; E/C/F/TDF = elvitegravir/kobicistat/emtricitabin/tenofovirdizoproksilfumarat a Okvir 48. tjedna bio je između 294. i 377. dana (uključujući).
An improved renal safety profile was maintained through Week 96 in patients who switched to Genvoya compared with those who stayed on a tenofovir disoproxil-containing regimen. 
Poboljšani profil sigurnosti primjene za bubrege održan je do 96. tjedna u bolesnika koji su prešli na lijek Genvoya u usporedbi s onima koji su ostali na režimu s tenofovirdizoproksilom.
Cobicistat reversibly inhibits MATE1, and concentrations of metformin may be increased when co-administered with Genvoya. 
Kobicistat reverzibilno inhibira MATE1, stoga se koncentracije metformina mogu povećati s istodobnom primjenom lijeka Genvoya.
Genvoya should not be co-administered with other antiretroviral medicinal products. 
Genvoya se ne smije primjenjivati istodobno s drugim antiretrovirusnim lijekovima.
 If you are taking any of these medicines, do not take Genvoya and tell your doctor immediately. 
 Ako uzimate bilo koji od ovih lijekova, nemojte uzimati lijek Genvoya i odmah o tome obavijestite svog liječnika.
• antacids, used to treat heartburn or acid reflux (see also section 3, How to take Genvoya). 
• antacide, primjenjuju se za liječenje žgaravice ili refluksa kiseline (također pogledajte dio 3,
It is not known whether cobicistat, emtricitabine, or tenofovir alafenamide are inhibitors of other UGT enzymes. 
Nije poznato jesu li kobicistat, emtricitabin ili tenofoviralafenamid inhibitori drugih UGT enzima.
When corrected for protein binding, unbound (free) plasma concentrations of tenofovir alafenamide in severe hepatic impairment and normal hepatic function are similar. 
Nakon korekcije za vezanje na proteine, koncentracije nevezanog (slobodnog) tenofoviralafenamida u plazmi kod teškog oštećenja funkcije jetre slične su onima kod normalne funkcije jetre.
At screening, 42% of patients were receiving FTC/tenofovir disoproxil plus atazanavir (boosted by either cobicistat or ritonavir), 32% of patients were receiving E/C/F/TDF, and 26% of patients were receiving EFV/FTC/tenofovir disoproxil. 
Pri probiru je 42% bolesnika primalo FTC/tenofovirdizoproksil plus atazanavir (pojačan ili kobicistatom ili ritonavirom), 32% bolesnika primalo je E/C/F/TDF te je 26% bolesnika primalo EFV/FTC/tenofovirdizoproksil.
The mean plasma to blood drug concentration ratio was 1.37. 
Omjer srednje vrijednosti koncentracije lijeka u plazmi i koncentracije lijeka u krvi iznosio je 1,37.
Dose modifications are not necessary when rosuvastatin is administered in combination with Genvoya. 
Izmjene doze nisu potrebne kada se rosuvastatin primjenjuje u kombinaciji s lijekom Genvoya.
Of the patients who were HBeAg positive at baseline, 1/30 (3.3%) achieved seroconversion to anti-HBe at Week 48. 
Od bolesnika koji su na početku bili HBeAg pozitivni, 1/30 (3,3%) postiglo je serokonverziju na anti-HBe u 48. tjednu.
Following oral administration of boosted [14C]-elvitegravir, elvitegravir was the predominant species in plasma, representing ~94% of the circulating radioactivity. 
Nakon peroralne primjene pojačanog [14C]elvitegravira, elvitegravir je bio najzastupljeniji u plazmi, predstavljajući ~ 94% cirkulirajuće radioaktivnosti.
In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. 
U bolesnika zaraženih HIV-om s teškom imunodeficijencijom u vrijeme uvođenja CART može doći do upalne reakcije na asimptomatske ili rezidualne oportunističke patogene, koja može uzrokovati ozbiljna klinička stanja ili pogoršanje simptoma.
Sofosbuvir metabolite GS-566500: 
Metabolit sofosbuvira GS-566500: AUC: ↔